source
- FDA review flags limited efficacy of Revolution's pancreatic cancer drug Rasonque, shares drop 6%Shares of Revolution Medicines fell about 6% after the Food and Drug Administration released review documents that suggest its pancreatic cancer therapy Rasonque may not work as well in all patient…
- RevMed's Rasonque shows weaker response in common KRAS pancreatic cancer mutation, shares fall over 6%New data from Revolution Medicines indicates that its KRAS inhibitor Rasonque had a reduced response rate in patients whose pancreatic tumors carry the most common KRAS mutation. The subgroup resp…